

ARTICLE OPEN



Antibody responses to the RTS,S/AS01_E vaccine and *Plasmodium falciparum* antigens after a booster dose within the phase 3 trial in Mozambique

Lina Sánchez^{1,2}, Marta Vidal¹, Chenjerai Jairoce^{1,3}, Ruth Aguilar¹, Itziar Ubillos¹, Inocencia Cuamba³, Augusto J. Nhabomba³, Nana Abo Williams¹, Núria Díez-Padrís¹, David Cavanagh⁴, Evelina Angov⁵, Ross L. Coppel⁶, Deepak Gaur^{7,8}, James G. Beeson⁹, Sheetij Dutta⁵, Pedro Aide¹⁰, Joseph J. Campo^{1,3}, Gemma Moncunill^{1,3,10} and Carlota Dobaño^{1,3,10}

The RTS,S/AS01_E vaccine has shown consistent but partial vaccine efficacy in a pediatric phase 3 clinical trial using a 3-dose immunization schedule. A fourth-dose 18 months after the primary vaccination was shown to restore the waning efficacy. However, only total IgG against the immunodominant malaria vaccine epitope has been analyzed following the booster. To better characterize the magnitude, nature, and longevity of the immune response to the booster, we measured levels of total IgM, IgG, and IgG₁₋₄ subclasses against three constructs of the circumsporozoite protein (CSP) and the hepatitis B surface antigen (HBsAg, also present in RTS,S) by quantitative suspension array technology in 50 subjects in the phase 3 trial in Manhíça, Mozambique. To explore the impact of vaccination on naturally acquired immune responses, we measured antibodies to *P. falciparum* antigens not included in RTS,S. We found increased IgG, IgG1, IgG3 and IgG4, but not IgG2 nor IgM, levels against vaccine antigens 1 month after the fourth dose. Overall, antibody responses to the booster dose were lower than the initial peak response to primary immunization and children had higher IgG and IgG1 levels than infants. Higher anti-Rh5 IgG and IgG₁₋₄ levels were detected after the booster dose, suggesting that RTS,S partial protection could increase some blood stage antibody responses. Our work shows that the response to the RTS,S/AS01_E booster dose is different from the primary vaccine immune response and highlights the dynamic changes in subclass antibody patterns upon the vaccine booster and with acquisition of adaptive immunity to malaria.

npj Vaccines (2020)5:46; <https://doi.org/10.1038/s41541-020-0192-7>

INTRODUCTION

Despite the great reduction in malaria cases in the last 15 years, thanks to the combination of multiple control measures, it is estimated that 219 million malaria cases and 435,000 deaths occurred in 2017, mostly associated with *Plasmodium falciparum*¹. Importantly, 90% of these deaths concentrated in sub-Saharan Africa and a large proportion occurred in children under 5 years. Owing to the concerning rise of parasite resistance to antimalarial drugs and vector resistance to insecticides^{1,2} and stalling progress in reducing malaria since 2016^{1,2}, integration of a malaria vaccine with other preventive measures will be a useful addition to control disease burden in the future.

Currently, the pre-erythrocytic RTS,S/AS01_E vaccine is the most advanced, having shown consistent but partial vaccine efficacy (VE) that wanes over time and is less effective in infants compared to children³. RTS,S/AS01_E contains a fusion protein including the central tandem repeat (NANP) and the C-terminal (C-term) regions of the *P. falciparum* circumsporozoite protein (CSP), and the hepatitis B virus surface antigen (HBsAg). It is expressed together with HBsAg, and injected in combination with the AS01 adjuvant system⁴. The vaccine was tested in a phase 3 clinical trial of a 3-dose immunization schedule (month [M] 0, M1 and M2) with a fourth dose 18 months after primary vaccination (M20)³, with the

booster dose partly restoring the waning VE. Specifically, VE for the 3-dose immunization schedule was 35.2% in children and 20.3% in infants up to M32 of the study, but VE waned over time with a VE of 16.1 and 7.6%, respectively, when considering only the period from M20 to M32. In children and infants who received the booster dose, waning VE was restored to overall levels of 43.9 and 27.8%, respectively³. In order to understand why protection offered by RTS,S is suboptimal and continue efforts to improve it, there is a need to decipher the mechanisms of protection elicited by the vaccine. It has been shown that antibody levels are involved in the vaccine-induced immunity, but they do not fully explain the protective effect of the vaccine^{5,6}. Thus far, the study of antibody response in trials performed in endemic areas has been largely focused on IgG levels against the NANP repeat region of CSP, with the exception of our previous work assessing more generally subclass responses to NANP and to other antigens after primary vaccination in the phase 3 trial⁷⁻⁹.

Characterizing responses by other antibody isotypes, subclasses, and responses to different epitopes may provide in depth understanding of the immune response to the vaccine and the mode of action. Antibody levels are not the sole means to determine vaccine mechanisms of action. Characteristics like the balance between isotypes or subclasses of the antibodies are

¹ISGlobal, Hospital Clínic—Universitat de Barcelona, Barcelona, Catalonia, Spain. ²UnivLyon, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France. ³Centro de Investigação em Saúde de Manhíça (CISM), Maputo, Mozambique. ⁴Institute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Edinburgh, UK. ⁵U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA. ⁶Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC, Australia. ⁷Malaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India. ⁸Laboratory of Malaria and Vaccine Research, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India. ⁹Burnet Institute, Melbourne, VIC, Australia. ¹⁰These authors contributed equally: Gemma Moncunill, Carlota Dobaño. ✉email: gemma.moncunill@isglobal.org; carlota.dobano@isglobal.org

important because of their varying effector functions¹⁰. For instance, some IgG subclasses act as cytophilic while others have non-cytophilic functions¹⁰, influencing the roles of Fc-mediated functions such as complement fixation and phagocytosis¹¹. Determining which type of response is detrimental or beneficial could further inform which responses could be modified to enhance the efficacy of the vaccine.

The epitope specificity of the antibody response is also relevant. There is clear evidence that NANP is related to VE⁶ but other regions could also mediate protection. Avidity of IgG to the CSP C-term has been associated with protection in African children¹², and C-term and not the NANP-repeat-specific antibodies have been reported to be the main mediators of phagocytic activity in naive adults¹³. Furthermore, antibodies to both C-term and NANP-repeat can mediate complement fixation in children, suggesting both regions are important for functional activity^{14,15}.

Additionally, studying the response to *P. falciparum* blood stage antigens not present in the vaccine is relevant to determine the effect of the vaccine on naturally acquired immunity (NAI), developed from continuous parasite exposure. It has been hypothesized that vaccination could (1) decrease NAI by reducing the exposure to the parasite, which could mean individuals are left vulnerable in the long term due to the waning efficacy of the vaccine³, as predicted for other malaria prevention tools¹⁶, or (2) increase NAI by allowing subclinical exposure to the parasite due to the partial efficacy of the vaccine^{9,17}.

Here, we used samples from the phase 3 trial at the time of the booster dose (M20) and onwards from a subgroup of subjects in Manhica, Mozambique, to characterize the effect of the RTS,S/AS01_E booster dose on different antibody responses. We evaluated total IgM, IgG and IgG₁₋₄ subclasses to vaccine and vaccine-unrelated *P. falciparum* blood stage antigens. Data were

combined with those from the primary vaccine response previously assessed⁷⁻⁹ to display the kinetics from baseline (M0) until M32.

RESULTS

Short- and long-term booster immunogenicity

The RTS,S/AS01_E booster dose increased IgG, IgG1, IgG3, and IgG4 levels against all vaccine antigens 1 month (M21) after its administration (M20), but it did not increase IgG2 nor IgM levels (Figs. 1 and 2; and Supplementary Table 1). The increase in antibody levels was significant both when comparing the levels pre-booster at M20 and M21 of the same individual, and when comparing the levels at post-booster M21 of the RTS,S booster group (R3R) to those of the individuals who did not receive a booster (R3C), except for IgG3 CSP NANP and IgG3 CSP full length (FL) for the latter comparison. At M21, the highest levels were against FL CSP, followed by the CSP NANP region, the CSP C-term and HBsAg. The predominant subclass was IgG1 followed by IgG3, then lower levels of IgG2 and least for IgG4.

Longer-term immunogenicity was measured 1 year after the administration of the booster (M32). IgG and IgG1 (but not IgG3) levels against vaccine antigens in the R3R group remained above the R3C group, except for IgG1 NANP (Figs. 1 and 2; and Supplementary Table 1). Similar to the pattern at M21, IgG2 and IgM levels were not higher in R3R at M32. For IgG4, levels were significantly higher in R3R compared to R3C only for CSP C-term and HBsAg. In comparison to the group that did not receive any RTS,S dose (C3C), the R3R and R3C groups levels at M32 remained higher for most antigens and IgG subclasses, except HBsAg IgG2 and IgG3, and NANP IgG3.




Fig. 1 RTS,S/AS01_E booster and long-term immunogenicity against vaccine antigens: total IgG, IgG1-2 subclasses for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum × value and Q3 + 1.5 × IQR, lower whisker as the largest between minimum × value and Q1 – 1.5 × IQR, and log₁₀(geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p-values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C (red): three doses of RTS,S/AS01_E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.




Fig. 2 RTS,S/AS01_E booster and long-term immunogenicity against vaccine antigens: IgG3-4 subclasses and IgM for CSP constructs and HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and \log_{10} (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C (red): three doses of RTS,S/AS01E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

Antibody kinetics through the entire study follow-up

When comparing the booster response (M21) to the primary vaccination response (M3), the group that received the booster had a lower peak in IgG, IgG1 and IgG3 levels after the booster than after primary vaccination (Figs. 3 and 4; and Supplementary Figs. 1 and 2). In contrast, IgG4 levels against CSP constructs showed higher levels after the booster dose than after primary vaccination, and overall levels increased in time. The opposite happened with HBsAg where IgG4 levels decreased with time and were higher at M3 than at M21. Although primary vaccination increased IgG2 and IgM levels, the booster dose did not increase them.

The decrease in anti-CSP levels from primary vaccination to M20 was larger for IgG3 than for IgG and IgG1; the mean decreases for anti-NANP IgG and IgG1 was around $1.5 \log_{10}$ median fluorescent intensity (MFI) while for IgG3 it was around $2.5 \log_{10}$ MFI. IgG2 levels remained more stable after the primary vaccination and did not increase or decrease vastly after M3. Remarkably, IgG4 levels against CSP FL and C-term at M20 were slightly higher than levels at M3 although this effect was not observed in the C3C group.

The levels of IgG and IgG₁₋₄ to CSP in RTS,S/AS01_E vaccination groups (R3), with or without booster, were higher for most post-vaccination time points than the levels in the comparator group. IgM levels were higher only at M3 in the R3 groups compared to the C3C group.

Factors affecting immunogenicity

Age. Children who received RTS,S/AS01_E either with or without a booster had higher IgG and IgG1 levels against CSP antigens than infants throughout the study period (Supplementary Figs. 1–6 and Supplementary Table 2). Without booster, IgG3 levels to NANP and FL CSP, but not C-term, were higher in children than infants. In

contrast, we did not detect differences in IgG3 levels between age groups after booster immunization. Most of the differences observed were not statistically significant but there were consistent patterns, e.g., for the same isotype/subclass and antigen, levels were lower in infants than children and all comparisons were $p < 0.05$ before adjustment for multiple testing. We did not detect a significant influence of age on IgG2, IgG4, or IgM levels in any group after the booster, except for NANP IgG4 levels in the R3R group that were higher in children. Likewise, we did not detect significant differences in antibody levels against HBsAg between age groups.

Malaria episodes. We compared the antibody levels at M20, M21 and M32 in individuals who had either presented or not with clinical malaria before M20 (Figs. 5–7 and Supplementary Table 3). None of the comparisons were statistically significant after adjusting for multiple testing. At M20 we did not detect any significant difference between individuals who presented or not with prior clinical malaria in the RTS,S vaccinees. In the R3R group at M21 there was a pattern for lower anti-CSP FL and anti-C-term IgG, IgG1, IgG3, IgG4 and IgM levels, and anti-NANP IgG4 levels ($p < 0.05$ before adjustment) in individuals who had clinical malaria. For the R3C group at M21, individuals who presented with clinical malaria before M20 had lower anti-CSP IgG and IgG1 mean levels against CSP antigens, and lower IgG3 levels against CSP FL ($p < 0.05$ before adjustment). In contrast, IgM levels were higher in plasma from previous malaria cases but this was not statistically significant. In the C3C group, IgG and IgG₁₋₃ to FL CSP and NANP were higher in the subjects with previous malaria cases but this difference was not statistically significant after adjusting for multiple testing. Lower levels of IgG, IgG1, and IgG3 to HBsAg were also observed in R3C at M20, M21, and M32 in the previous




Fig. 3 Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, and IgG2. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, and lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$. The y-axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals⁷, thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster at month 20. R3C (red): three doses of RTS,S/AS01_E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

malaria cases (Supplementary Fig. 7), but these differences were not statistically significant.

The study was not designed to assess associations with future malaria risk but we had some provisional findings. IgG2 and IgG3 to vaccine antigens in the R3R group at M21 were higher in those subjects with subsequent clinical malaria, but this difference was not statistically significant. Only for anti-NANP IgG2 and anti-HBsAg IgG2 and IgG3 levels, differences had $p < 0.05$ before adjusting for multiple testing (Figs. 8–11 and Supplementary Table 3). In contrast, IgG1 and IgG4 levels to NANP and CSP FL in the R3R group at M21 were lower in malaria cases, but not significantly. An opposite pattern consisting of higher levels in malaria cases was observed in the R3C group. Fold-change in IgM levels against CSP constructs from M20 to M21 in the R3R group was lower in malaria cases ($p < 0.05$ before adjustment) (Supplementary Figs. 8 and 9). This contrasted to what was observed in the R3C group who had higher fold-change in IgM levels in malaria cases. Additionally, the fold-change in anti-HBsAg IgG3 levels was higher in malaria cases ($p < 0.05$ before adjustment). In most cases, there was no statistically significant difference between subjects presenting with clinical malaria after M21 and those who did not.

Effect of RTS,S booster vaccination on antibodies to blood stage antigens

For most of the blood stage antigens we studied, we could not detect differences in antibody levels before and after the booster dose, nor when comparing the R3R, R3C, and C3C groups. There were some differences ($p < 0.05$ before adjustment) in antibody levels at M3 and/or M21 for MSP5, MSP1₄₂, MSP1-BL2, Rh4.2,

EBA140 and EBA175 (Supplementary Figs. 10–15 and Supplementary Table 4). Interestingly, Rh5 antibodies showed a consistent change in levels after the RTS,S booster for IgG and all IgG subclasses, with higher levels in the R3R group (Figs. 12 and 13; Supplementary Fig. 16 and Supplementary Table 4). In the case of IgG, IgG1 and IgG2 the differences were significant both in the short (M21) and long (M32) term, while for IgG3 and IgG4 differences were only at M21 with $p < 0.05$ before adjustment. Curiously, overall levels diminished over follow-up with the exception of IgG4.

Age did not have a significant effect on the antibody levels against the studied blood stage antigens (Supplementary Figs. 16–23 and Supplementary Table 5). Individuals who were classified as having had a case of clinical malaria before M20 tended to have higher levels of antibody to blood stage antigens at M20–32 but this difference was not statistically significant (Supplementary Figs. 24–30 and Supplementary Table 6). The most remarkable difference was the levels of MSP1₄₂ that acted as a marker for malaria exposure, showing higher levels in those who had clinical malaria, in particular for IgG, IgG1 and IgG2. Overall, the responses showed a general pattern of higher levels at all time points for all vaccination groups in individuals who subsequently presented with a malaria case but it was not significant (Supplementary Figs. 31–37 and Supplementary Table 6).

DISCUSSION

This study confirms that the RTS,S/AS01_E booster dose increases total IgG levels against vaccine antigens and elucidates its




Fig. 4 Antibody responses against vaccine antigens for months (M) 0, 3, 20, 21, and 32 for IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, and lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$. The y-axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster at month 20. R3C (red): three doses of RTS,S/AS01_E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

differing effect on IgG subclasses and IgM not previously studied. We describe for the first time the long-term RTS,S/AS01_E antibody response to different antigens and CSP epitopes. The booster dose increased total IgG, IgG1, IgG3, and IgG4 for all vaccine antigens compared to pre-booster levels, and they remained above the levels of non-vaccinated individuals during the entire follow-up period. Remarkably, the fourth dose did not induce an increase in IgG2 levels (although the primary vaccination did) but it increased IgG1 and IgG3 levels, which may explain how the booster led to higher efficacy overall. IgG1 and IgG3 can effectively fix complement and promote interactions with Fc γ -receptors on phagocytes¹⁰, which could be contributing to RTS,S-induced protection. IgG2 and IgG4, on the contrary, are non-cytophilic antibodies unable to fix complement and to interact with Fc γ -receptors¹⁰.

The profile of antibody responses seems to be epitope-specific. Previously, the bulk of studies had only evaluated NANP antibodies and have provided clear evidence that NANP antibodies are associated with protection⁶, being the established immunodominant region of the vaccine antigen⁴. However, there is evidence that antibodies against C-term are involved in phagocytic activity in US naive adults¹³, and RTS,S vaccine-induced antibodies to the C-term among children can promote complement fixation¹⁴. Also, in our previous work we have found that post-primary vaccination, the avidity of the IgG response to CSP C-term was associated with protection¹². Here, we show that the booster dose increases levels of antibodies against both NANP and the C-term, and that the responses against these two regions may behave differently. Antibody levels to NANP were higher

compared to C-term, but the proportional increase 1 month after the booster dose was not different.

Previously it was reported that the IgG levels to NANP were increased by the booster dose, but the peak post-booster levels were lower than following primary vaccination⁶. In this study, we found similar results for IgG subclasses—there was boosting but levels overall were lower than following primary vaccination⁷. Remarkably, IgG4 levels against CSP kept increasing with time. The RTS,S pattern differs to other vaccines in which the peak for the booster response is higher than the peak for the primary vaccination¹⁸. The unusual response to the booster dose could be caused by different factors. These factors include the response to primary vaccination¹⁹, but also the booster dose or the primary vaccination schedule^{20,21}. For instance, it has been reported that for some vaccines high residual levels of vaccine antibodies have a negative effect on the post-booster response¹⁹; however, our study did not find evidence for a negative correlation between M20 and M21 antibody levels (Supplementary Figs. 38 and 39). There is also evidence from the response to a Meningococcal conjugated vaccine that primary vaccination administered with a short interval doses might lead to higher antibodies at the primary vaccination peak, but a higher number of doses lead to a lower post-booster response²⁰. The effect of the dosing interval on the responses to the RTS,S vaccine was observed on a phase 2 trial that compared a 0, 1, 2 months vs. 0, 1, 7 months schedule and showed that the highest peak was observed following the 0, 1, 2 month schedule²¹. Also, the booster dose might induce different IgG subclass patterns to primary vaccination because it is acting on immune memory cells such as B memory cells and it might be inducing class switch and increasing antibody affinity^{19,22}.




Fig. 8 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP FL at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and \log_{10} (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). *p*-values were adjusted for multiple comparisons, but none was significant. Only *p*-values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C: three doses of RTS,S/AS01_E and a comparator booster. C3C: three doses of a comparator vaccine and a comparator booster.

On the contrary, 1 month after receiving the RTS,S booster dose, anti-HBsAg IgG2 and IgG3 levels appeared as risk factors for future malaria episodes, further indicating that the nature and role of responses may differ following a primary and a booster immunization.

The analysis of the phase 3 clinical trial found that children who did not receive the booster dose were at higher risk of severe malaria than the comparator (non-RTS,S) group³. It was hypothesized that the primary vaccination had prevented vaccinees from acquiring natural immunity, as has been predicted for other malaria prevention tools¹⁶, increasing the risk of severe malaria in those individuals in whom infection reached the erythrocytic stage. However, on a longer follow-up study of up to 7 years on 3 of 11 sites, no increased risk was found for severe malaria between those groups that received the RTS,S/AS01 vaccine and the control

group³¹. Antibody responses to asexual blood stage antigens have been studied previously with samples from phase 2 clinical trials and showed a reduced antibody response in RTS,S vaccinees, but these trials did not include a booster dose^{17,32,33}. We detected a decreased antibody response to certain vaccine-unrelated *P. falciparum* antigens after primary vaccination in the phase 3 trial as well^{8,9}. However, we also observed an induction of antibody responses to other *P. falciparum* antigens following RTS,S vaccination (MSP1-BL2, EBA140, EBA175, and Rh4.2), which could contribute to malaria protection^{8,9}. Here, we did not find consistent differences in the NAI response between booster groups except for Rh5. Interestingly and in line with our previous results, Rh5 IgG and IgG1-2 levels were higher in the RTS,S booster group than in the comparator vaccine groups at M21 and M32, and R3C levels were either higher or did not differ from C3C.




Fig. 9 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP NANP at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and \log_{10} (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values < 0.05 before adjustment are shown. The y -axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C: three doses of RTS,S/AS01_E and a comparator booster. C3C: three doses of a comparator vaccine and a comparator booster.

This finding requires future investigation to understand the basis and clinical relevance of this effect, especially since Rh5 is a leading vaccine candidate³⁴, and because Rh5 antibody concentrations need to be very high to actually confer protection³⁵. However, these observations are important as they may explain why an anti-sporozoite infection vaccine also protects against clinical disease in the parasite blood stage, considering that Rh5 plays an essential role during erythrocyte invasion by *P. falciparum* merozoites^{36–38}. Additionally, IgG to MSP5 showed higher levels after RTS,S booster dose compared to the comparator booster group, but this was not statistically significant.

Our findings are limited because of a small sample size and because data were obtained only for Manhica. Therefore, a larger longitudinal study with samples from different sites is necessary to corroborate these data. This is particularly important in our case

because there are some special considerations about Manhica that limits the generalization of these findings: (1) at the time of the study malaria transmission was low^{3,39}, (2) there were unexpected results of VE in the phase 3 clinical trial, i.e., VE was lower in the R3R than in the R3C group, contrary to most sites, and (3) Manhica has a high HIV prevalence⁴⁰. HIV infection was associated with a reduced immunogenicity to the vaccine in a phase 3 trial exploratory analysis but it was concluded that HIV-infected children should not be excluded from RTS,S vaccination⁴¹.

Despite the constraints, our study provides new and interesting clues to the immune response elicited by the RTS,S booster dose. Additionally, avidity and functional antibody responses should be assessed, and these results integrated with cellular data to address memory responses induced by the booster. This information is necessary for a deeper understanding of the mechanisms of

Post-booster malaria cases




Fig. 10 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for CSP C-term at month (M) 20, 21, and 32 for RTS,S/AS01E vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and \log_{10} (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values < 0.05 before adjustment are shown. The y-axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01E and a RTS,S/AS01E booster. R3C: three doses of RTS,S/AS01E and a comparator booster. C3C: three doses of a comparator vaccine and a comparator booster.

action of the vaccine, as well as the determination of the factors causing partial and short VE. Results of these studies are required for the rational design and deployment of improved CSP-based vaccines and other malaria vaccines with an increased and long-term efficacy.

METHODS

Population and study design

This study was performed using plasma samples previously collected from subjects in Manhica, Mozambique, a site of low malaria transmission intensity^{3,39}, as part of the MAL067 study ancillary to the phase 3 randomized clinical trial MAL055 (NCT00866619)³. A subset of 50 individuals (24 children 5–17 months and 26 infants 6–12 weeks) was selected from those previously analyzed^{7–9} who had available antibody

data from M0 (baseline) and M3 (one month after third dose) and plasma samples for M20 (booster dose), M21, and M32 (Supplementary Table 7). The subjects had either received three doses of the RTS,S/AS01E vaccine and a RTS,S/AS01E booster (R3R, $n = 14$) at M20, three doses of RTS,S/AS01E and a comparator booster (R3C, $n = 19$), or three doses and a booster of a comparator vaccine (C3C, $n = 17$) (Supplementary Fig. 40). The comparator vaccines used in the primary series were a Meningococcal C Conjugate Vaccine (Menjugate™) in the 6–12 weeks age category, and a cell-culture rabies vaccine (VeroRab™) in the 5–17 months age category. The booster comparator was Menjugate™ for both age groups. Clinical malaria cases were detected by passive case detection and defined as fever of at least 37.5 °C and any asexual *P. falciparum* parasitemia by microscopy³. The prevalence of HIV infection in the Manhica area was around 40% in adults⁴⁰. HIV infection was not a protocol exclusion/inclusion criteria, but only healthy children were included in the study. HIV testing was not a trial procedure. The study protocol was approved by the Ethics Committees of

Post-booster malaria cases




Fig. 11 Immunogenicity stratified by clinical malaria after M21: total IgG, IgG1-4 subclasses and IgM for HBsAg at month (M) 20, 21, and 32 for RTS,S/AS01 vaccinees with (R3R) and without (R3C) booster, and comparator (C3C). Stratified analysis by malaria after M21, subjects who presented with clinical malaria (M = blue) and subjects without malaria (NM = red). Subjects who presented with clinical malaria before M20 are represented with green and orange squares. Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and \log_{10} (geometric mean(MFI)) (diamond). Non-parametric tests were used to compare levels with or without clinical malaria (NM vs. M). p -values were adjusted for multiple comparisons, but none was significant. Only p -values < 0.05 before adjustment are shown. The y -axis is in logarithm 10 scale. R3R: three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C: three doses of RTS,S/AS01_E and a comparator booster. C3C: three doses of a comparator vaccine and a comparator booster.

PATH-MVI (REC) in the US, Hospital Clínic in Spain (CEIm) and the CNBS in Mozambique, and written informed consent was obtained from parents or guardians before recruitment.

Antibody luminex assays

Antibody response was analyzed using a quantitative suspension array technology (qSAT). MAGPlex beads were coupled separately to: three CSP constructs (FL, C-term, NANP-repeat region) and HBsAg that are antigenic components of the RTS,S vaccine; seven *P. falciparum* blood stage antigens (MSP1 [block 2 and MSP1₄₂ fragments, 3D7 strain], MSP5, EBA140, EBA175 region 3-5, Rh4.2 and Rh5) that were shown to be affected by vaccination in our previous studies⁷⁻⁹ and/or that are leading vaccine candidates; and Glutathione S-transferase (GST) as a control for antigens co-expressed with a GST tag (Supplementary Table 8)⁴². The coupling of the beads to the antigens was performed as described previously⁴³.

Antigen-coupled beads were added to a 96-well μ Clear® flat bottom plate (Greiner Bio-One) in multiplex (1000 microspheres/analyte/well) resuspended in 50 μ L of PBS, 1% BSA, 0.05% Azide pH 7.4 (PBS-BN). Fifty microliters of sample, negative or positive control were added to wells and incubated overnight at 4 °C in a shaker protected from light. Plates were washed three times with 200 μ L/well of wash buffer (PBS-Tween 20: 0.05%) using a manual magnetic washer. Then, 100 μ L of biotinylated secondary antibody were added diluted in PBS-BN: anti-human IgG 1/2500 (B1140 Sigma), anti-human IgG1 1/4000 (ab99775 Abcam), anti-human IgG3 1/1000 (B3523 Sigma), and anti-human IgM 1/1000 (B1265 Sigma). For IgG2 and Ig4, mouse anti-human IgG2 1/500 and IgG4 1/500 (MA1-34755 and MA5-16716 Thermo Fisher), respectively, were added, followed by biotinylated goat anti-mouse IgG 1/40,000 for IgG2 and 1/10,000 for IgG4 (B7401 Sigma) in PBS-BN. All antibody incubations were performed for 45 min, at room temperature, in agitation and protected from light. Again, plates were washed as before and 100 μ L/well streptavidin-R-




Fig. 12 RTS,S/AS01_E booster and long-term immunogenicity against the blood stage antigen Rh5: total IgG, IgG1-4 subclasses and IgM at month (M) 20, 21, and 32 for RTS,S/AS01 vaccines with (R3R) and without (R3C) booster, and comparator (C3C). Boxplots with medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$, lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$, and $\log_{10}(\text{geometric mean(MFI)})$ (diamond). Non-parametric tests were used to compare the booster response (M20 vs. M21) and the long-term immunogenicity (M21 vs. M32), as well as to compare the R3C and R3R groups at each timepoint. Only p -values < 0.05 after adjustment for multiple testing are shown. The y-axis is in logarithm 10 scale. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster. R3C (red): three doses of RTS,S/AS01_E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

phycoerythrin 1/1000 (42250 Sigma) in PBS-BN was added to all wells and incubated 30 min, at room temperature, in agitation and protected from light. Plates were washed as before and resuspended in 100 μ L/well of PBS-BN. Plates were stored at 4 $^{\circ}$ C overnight protected from light and read the next day using the Luminex xMAP[®] 100/200 analyzer; at least 50 microspheres per analyte were acquired per sample and Report Gain was set as High PMT.

For IgG, IgG1, IgG3, and IgM, 20 serial dilutions 1:2 of a positive control were used to perform antigen-subclass-specific standard curves. For IgG2, 16 serial dilutions 1:2 were used. For IgG4, no standard curve was performed and only one positive control dilution was included. The positive control consisted of a WHO Reference Reagent for anti-malaria *P. falciparum* human serum (NIBSC code: 10/198)^{42,44} at 1:50 mixed with a pool of plasmas from RTS,S/AS02 vaccinated children^{42,45} with high IgG levels against CSP at 1:200. Blanks were added to each plate in duplicates and two negative controls samples from malaria-naïve adults were added in each plate. Test samples were assayed at three dilutions for IgG (500, 20,000, 500,000), IgG1, IgG3 (100, 2500, 100,000) and IgM (100, 1000, 25,000) to ensure that at least one dilution lie in the linear range of the respective standard curve, i.e., close to the highest slope between two dilution points. Owing to the low levels previously observed in these samples for IgG2 and IgG4 in Ubilos et al.,⁷ only one dilution (1/50) was used. Sample distribution across plates was designed to ensure a balanced distribution of vaccination groups, sex, age cohorts, and malaria cases. The three time points for each individual and the respective dilutions were placed on the same plate. Data were captured using xPonent software, and antibody levels were measured as MFI.

Data pre-processing. The standard curve for each antigen-isotype/subclass-plate was estimated using the drLumi R package flow⁴⁶, fitted in a 4- or 5-parameter logistic (4-PL or 5-PL) regression model, and data points logarithmically transformed. To select the sample dilution for IgG,

IgG1, and IgG3 in the linear part of the sigmoidal curve (antigen, isotype/subclass and plate specific), an algorithm that detects the two points with the highest slope between them was used. The slope was computed as: $m = (MFI_i - MFI_{i+1}) / (\text{dilution_factor}_i - \text{dilution_factor}_{i+1})$. The mean MFI value of the two points was computed and used as the reference value, but the standard curves were visually inspected and if the model did not converge, the $R^2 < 0.9$ or the curve maximum values were $< 15,000$ MFI, a 15,000 MFI reference value was set instead of the highest slope criteria. The nearest MFI of the test sample to the reference value was determined and the corresponding dilution was selected. Since only one dilution was used for IgG2 and IgG4, the standard curves were not used to select a dilution. The MFI measurement of the selected dilution was corrected multiplying by its corresponding dilution factor and transformed to \log_{10} scale to stabilize the variance. Blank and GST signals were not subtracted. Blanks were used to measure background signal, and GST to assess for unspecific binding to the GST-fused antigens (CSP FL, CSP C-term, and CSP-NANP). Background values were below 500 MFI, and no correlation was found between IgG to GST and IgG to GST-fused antigens (Supplementary Figs. 41 and 42).

Statistical analysis

Descriptive comparisons of Ig isotype/subclass levels to specific antigens (\log_{10} transformed MFI) at each visit were done by boxplots with $\log_{10}(\text{geometric mean})$, medians, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$ and lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$. Wilcoxon-Signed Rank Test between M20 and M21 for the R3R vaccination group, and between M21 and M32 for the R3R and R3C vaccination groups were performed to determine if the antibody levels changed significantly 1 month and 1 year after the booster. Additionally, Mann-Whitney tests were performed to compare the R3R and R3C groups at each timepoint.




Fig. 13 Antibody responses against the blood stage antigen Rh5 for months (M) 0, 3, 20, 21, and 32 for IgG, IgG1, IgG2, IgG3, IgG4 and IgM. Boxplots with median, interquartile ranges (IQR), upper whisker as the smallest between maximum \times value and $Q3 + 1.5 \times IQR$ and lower whisker as the largest between minimum \times value and $Q1 - 1.5 \times IQR$. The y-axis is in logarithm 10 scale. Data from months 0 and 3 were obtained from a previous study in the same individuals [7], thus a batch effect might be present. R3R (green): three doses of RTS,S/AS01_E and a RTS,S/AS01_E booster at month 20. R3C (red): three doses of RTS,S/AS01_E and a comparator booster. C3C (blue): three doses of a comparator vaccine and a comparator booster.

p -values were adjusted for multiple testing using p_{adjust} on R^{47} by the Holm approach for IgG and for IgM to control for family wise error, and by the Benjamini–Hochberg approach for IgG1–4, altogether to control for the false-discovery rate since there were more tests. The comparisons between time points were corrected separately from the comparisons between vaccination groups, likewise the comparisons for vaccine antigens were corrected separately from blood stage antigens. Data for M0 and M3 from our previous study⁷ was used to analyze the kinetics of the antibody response throughout the 5 time points in the clinical trial. Adjusted p -values were considered significant when <0.05 . The qSAT assay of M20, M21, and M32 samples was performed in the same laboratory using the same reagents and under similar conditions as the assay of the M0 and M3 samples, but they were not executed at the same time and a smaller set of antigens was used.

Stratified analyses and Mann–Whitney tests for independent groups and Wilcoxon–Signed Rank Tests for paired samples were performed between age groups and between malaria cases and controls, for each timepoint. p -values were adjusted following the same strategy as above. There were no reported malaria cases between M20 and M21. The change in antibody levels between M20 and M21 was calculated as $\log_{10}MFI(M21) - \log_{10}MFI(M20)$ and compared between individuals who either did or did not present with clinical malaria after M21. All data analysis and plots were performed using R packages gridExtra⁴⁸, dplyr⁴⁹, ggplot2⁵⁰, tidyr⁵¹, and psych⁵².

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

The datasets generated in the current study are fully available at the Dipòsit Digital de la Universitat de Barcelona at <http://hdl.handle.net/2445/164777>.

Received: 22 November 2019; Accepted: 7 May 2020;
Published online: 04 June 2020

REFERENCES

1. WHO. *World Malaria Report 2018* (WHO, 2018).
2. Poirot, E. et al. Mass drug administration for malaria. *Cochrane Database Syst. Rev.* **12**, CD008846 (2013).
3. The RTS S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet* **386**, 31–45 (2015).
4. Cohen, J., Nussenzweig, V., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. *Hum. Vaccin.* **6**, 90–96 (2010).
5. The RTS S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. *PLoS Med.* **11**, e1001685 (2014).
6. White, M. T. et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. *Lancet Infect. Dis.* **15**, 1450–1458 (2015).
7. Ubilos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. *BMC Med.* **16**, 197 (2018).
8. Dobaño, C. et al. Differential patterns of IgG subclass responses to plasmodium falciparum antigens in relation to malaria protection and RTS,S vaccination. *Front. Immunol.* **10**, 439 (2019).
9. Dobaño, C. et al. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated *Plasmodium falciparum* antigens associated with protection against clinical malaria in African children: a case-control study. *BMC Med.* **17**, 157 (2019).
10. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. *Front. Immunol.* **5**, 520 (2014).

11. Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. *Mol. Immunol.* **67**, 171–182 (2015).
12. Dobaño, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. *Nat. Commun.* **10**, 2174 (2019).
13. Chaudhury, S. et al. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. *Malar. J.* **15**, 1–12 (2016).
14. Kurtovic, L. et al. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure. *BMC Med.* **17**, 45 (2019).
15. Kurtovic, L. et al. Human antibodies activate complement against *Plasmodium falciparum* sporozoites, and are associated with protection against malaria in children. *BMC Med.* **16**, 61 (2018).
16. Ghani, A. C. et al. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. *PLoS ONE* **4**, e4383 (2009).
17. Campo, J. J. et al. Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens. *PLoS ONE* **6**, e25779 (2011).
18. Siegrist, C.-A. & Lambert, P.-H. in *The Vaccine Book*. 33–42 (Elsevier, 2016).
19. Plotkin, S. A. Vaccines: the fourth century. *Clin. Vaccin. Immunol.* **16**, 1709–1719 (2009).
20. Borrow, R. et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. *Infect. Immun.* **71**, 5549–5555 (2003).
21. Asante, K. P. et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. *Lancet Infect. Dis.* **11**, 741–749 (2011).
22. Schure, R.-M. et al. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. *Clin. Vaccin. Immunol.* **20**, 1388–1395 (2013).
23. Noland, G. S. et al. Effect of transmission intensity and age on subclass antibody responses to *Plasmodium falciparum* pre-erythrocytic and blood-stage antigens. *Acta Tropica.* **142**, 47–56 (2015).
24. Valéa, I. et al. Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial. *Hum. Vaccin. Immunother.* 1–7 (2020). <https://doi.org/10.1080/21645515.2019.1695457>.
25. Goenka, A. & Kollmann, T. R. Development of immunity in early life. *J. Infect.* **71**, S112–S120 (2015).
26. Kollmann, T. R., Levy, O., Montgomery, R. R. & Goriely, S. Innate immune function by toll-like receptors: distinct responses in newborns and the elderly. *Immunity* **37**, 771–783 (2012).
27. Chaudhury, S. et al. Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis. *Sci. Rep.* **7**, 7998 (2017).
28. Geroldinger-Simic, M. et al. Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies. *J. Allergy Clin. Immunol.* **127**, 616–622.e1 (2011).
29. Leoratti, F. M. S. et al. Pattern of humoral immune response to *Plasmodium falciparum* blood stages in individuals presenting different clinical expressions of malaria. *Malar. J.* **7**, 186 (2008).
30. Aucan, C. et al. High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to *Plasmodium falciparum* malaria. *Infect. Immun.* **68**, 1252–1258 (2000).
31. Tinto, H. et al. Long-term incidence of severe malaria following RTS, S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. *Lancet Infect. Dis.* **3099**, 1–12 (2019).
32. Campo, J. J. et al. RTS,S vaccination is associated with serologic evidence of decreased exposure to *Plasmodium falciparum* liver- and blood-stage parasites. *Mol. Cell. Proteom.* **14**, 519–531 (2015).
33. Bejon, P. et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. *J. Infect. Dis.* **204**, 9–18 (2011).
34. Draper, S. J. et al. Malaria vaccines: recent advances and new horizons. *Cell Host Microbe* **24**, 43–56 (2018).
35. Payne, R. O. et al. Human vaccination against RH5 induces neutralizing anti-malarial antibodies that inhibit RH5 invasion complex interactions. *JCI Insight* **2**, e96381 (2017).
36. Reddy, K. S. et al. Multiprotein complex between the GPI-anchored CyRPA with PFRH5 and PFRipr is crucial for *Plasmodium falciparum* erythrocyte invasion. *Proc. Natl Acad. Sci.* **112**, 1179 LP–1184 (2015).
37. Reddy, K. S. et al. Bacterially expressed full-length recombinant *Plasmodium falciparum* RH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. *Infect. Immun.* **82**, 152–164 (2014).
38. Volz, J. C. et al. Essential role of the PFRh5/PFRipr/CyRPA complex during *Plasmodium falciparum* invasion of erythrocytes. *Cell Host Microbe* **20**, 60–71 (2016).
39. The RTS S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N. Engl. J. Med.* **365**, 1863–1875 (2011).
40. González, R. et al. HIV incidence and spatial clustering in a rural area of Southern Mozambique. *PLoS ONE* **10**, e0132053–e0132053 (2015).
41. Otieno, L. et al. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. *Vaccine* **38**, 897–906 (2020).
42. Ubillos, I. et al. Optimization of incubation conditions of *Plasmodium falciparum* antibody multiplex assays to measure IgG, IgG1-4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies. *Malar. J.* **17**, 219 (2018).
43. Vidal, M., Aguilar, R., Campo, J. J. & Dobaño, C. Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple *Plasmodium falciparum* antigens. *J. Immunol. Methods* **455**, 41–54 (2018).
44. Bryan, D. et al. The establishment of a WHO reference reagent for anti-malaria (*Plasmodium falciparum*) human serum. *Malar. J.* **16**, 314 (2017).
45. Alonso, P. L. et al. Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial. *Lancet* **364**, 1411–1420 (2004).
46. Sanz, H. et al. drLumi: an open-source package to manage data, calibrate, and conduct quality control of multiplex bead-based immunoassays data analysis. *PLoS ONE* **12**, e0187901 (2017).
47. R Core Team. *R: A Language and Environment for Statistical Computing* (R Core Team, 2017).
48. Auguie, B. *gridExtra: Miscellaneous Functions for 'Grid' Graphics*. <https://cran.r-project.org/package=gridExtra> (2017).
49. Wickham, H., Francois, R., Henry, L. & Müller, K. *dplyr: A Grammar of Data Manipulation*. <https://cran.r-project.org/package=dplyr> (2017).
50. Wickham, H. *ggplot2: elegant graphics for data analysis*. *Wiley Interdiscip. Rev. Comput. Stat.* **3**, 180–185 (2011).
51. Wickham, H. & Henry, L. *tidyr: Easily Tidy Data with 'spread()' and 'gather()' Functions*. <https://cran.r-project.org/package=tidyr> (2018).
52. Revelle, W. *psych: Procedures for Personality and Psychological Research*. <https://cran.r-project.org/package=psych> (2018).

ACKNOWLEDGEMENTS

We are grateful to the Manhíça volunteers and their families; the clinical, field, and lab teams at CISM; the MAL067 Vaccine Immunology Consortium investigators; the hyper-immune plasma suppliers (NIBSC, UK); Hèctor Sanz for database management and statistical support. We thank the researchers from the labs that produced the recombinant proteins. We thank GlaxoSmithKline Biologicals S.A. for their support in the conduct of the MAL055 study. Work received funding from the NIH-NIAID (R01AI095789), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI17/02044) cofunded by FEDER funds/European Regional Development Fund (ERDF), and EVIMaLaR and AGAUR-Catalonia (2014 SGR991), and National Health and Medical Research Council of Australia (1077636 and 1092789). L.S., registered in the EMJMD LIVE (Erasmus+ Mundus Joint Master Degree Leading International Vaccinology Education, award 2015-2323), co-funded by the EACEA (Education, Audiovisual and Culture Executive Agency) of the European commission, received a scholarship from the EACEA. G.M. was a recipient of a Sara Borrell—ISCIII fellowship (CD010/00156) and had the support of the Department of Health, Catalan Government (SLT006/17/00109). C.J. was supported by an AGAUR-FI scholarship (2019 FI_B 00986) granted by the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya and co-funded with Social European Fund. ISGlobal is a member of the CERCA Program, Generalitat de Catalunya.

AUTHOR CONTRIBUTIONS

Designed the immunology study and protocols: C.D., J.J.C., G.M., R.A.; performed the clinical trial: P.A.; processed samples and/or data management: C.J., I.C., A.J.N., M.V., I.U., G.M., J.J.C., C.D.; managed the study: N.A.W., N.D., C.D.; produced antigens: D.C., E.A., R.L.C., D.G., J.G.B., S.D.; performed experiments: L.S., M.V.; supervised lab work: R.A.; performed statistical analysis: L.S. Wrote the first draft: L.S., G.M., C.D. Reviewed and approved the manuscript: all.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at <https://doi.org/10.1038/s41541-020-0192-7>.

Correspondence and requests for materials should be addressed to G.M. or C.D.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020, corrected publication 2022